AGM Statement

Abingdon Health PLC
15 December 2023
 

 

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

AGM Statement

 

York, U.K. 15 December 2023: Abingdon Health plc (AIM: ABDX, 'Abingdon' or 'the Company'), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), will hold its Annual General Meeting at 9.30 a.m. today at the Company's facilities at York Biotech Campus, Sand Hutton, York, YO41 1LZ.

 

Chris Yates, Chief Executive Officer, will address the meeting with the following statement: "We updated shareholders in October with our annual results to June 2023. At that time, I said that I believed Abingdon was well positioned to meet the growing demand of the lateral flow market, through both our CRO/CDMO offering, and through our complementary direct sales and distribution platform. This is proving to be the case as evidenced both by the number of customers and projects we are working with, and our continued revenue growth. We will provide a more comprehensive trading update in January 2024, but I am pleased to note that our revenue for H1 FY23/24 will be significantly higher than revenue for H1 FY22/23."

 

"We remain highly focused on continuing to grow our revenues and reducing our cash-burn in FY23/24 and beyond. Our ongoing priority is moving the Company to a positive cash flow position based on continued revenue growth and stringent cost control."

 

Enquiries

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Chris Hand, Non-Executive Chairman


 

 


Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Peter Steel, Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

+44 (0)7407 804 654

 

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract research (CRO) and contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. 

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings